EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

Impact of COVID-19 Monoclonal Antibody Therapy on Subsequent Vaccine-elicited SARS-CoV-2 Immune Responses

Davey M Smith iD, Isabelle R Weir, Sydney Ramirez iD, Camila H Coelho iD, Jennifer Manne-Goehler iD, Mariam Aziz, Constance A Benson, Xingye Wu iD, Randall Hyer, Preeti K Dhillon, Farhoud Faraji iD, Nathaniel Bloom iD und 14 weitere

The Journal of Infectious Diseases · 2026

DOI: 10.1093/infdis/jiag091 ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift The Journal of Infectious Diseases, 2026. Verfasst von Davey M Smith und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of California San Diego, La Jolla, California, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, COVID-19, COVID-19 Drug Treatment, COVID-19 Vaccines. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCATS NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

How anti-SARS-CoV-2 monoclonal antibodies (mAbs) change subsequent vaccine responses remains uncertain.

Methods

We conducted a prospective, phase IV, open-label study of adults who received mRNA-1273 or BNT162b2. Cohort 1 included outpatients with acute COVID-19 previously randomized to mAbs (tixagevimab/cilgavimab or amubarvimab/romlusevimab), camostat, or placebo in ACTIV-2/A5401. Cohort 2 included unvaccinated adults without reported prior COVID-19 and was analyzed as naïve or non-naïve by baseline neutralizing antibodies (nAbs). We measured binding IgG, nAbs, spike-specific memory B cells, and CD4+/CD8+ T cells at baseline and days 28, 56, and 140.

Results

Forty-three participants were analyzed. At day 140, nAb titers were lower among prior mAb recipients and COVID-19–naïve participants than among placebo/camostat recipients and those with evidence of prior infection (overall p=0.018). RBD-specific, but not spike-specific, memory B cells were reduced after prior mAb therapy at days 56 and 140. Frequency of spike-specific CD4+ and CD8+ T-cell responses did not differ by prior mAb exposure. Adverse events were mostly grade 1–2 and consistent with vaccine trials.

Conclusions

Prior anti-SARS-CoV-2 mAb treatment limits endogenous RBD-focused B-cell responses to later mRNA vaccination without measurably affecting T-cell immunity. Timing of vaccination after mAb therapy may matter and warrants study.

Trial registration

NCT04952402.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalCOVID-19COVID-19 Drug TreatmentCOVID-19 VaccinesAdultAgedFemaleHumansMaleMiddle Aged2019-nCoV Vaccine mRNA-1273Antibodies, NeutralizingAntibodies, ViralBNT162 VaccineCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesImmunoglobulin GProspective StudiesSpike Glycoprotein, Coronavirus

Substanzen

2019-nCoV Vaccine mRNA-1273Antibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralBNT162 VaccineCOVID-19 VaccinesImmunoglobulin GSpike Glycoprotein, Coronavirus

Autor:innen und Institutionen

  • Department of Medicine, University of California San Diego, La Jolla, California, USA.
  • Center for Biostatistics in AIDS Research in the Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
  • Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, California, USA.
  • Center for Vaccine Research and Pandemic Preparedness, Department of Microbiology, and Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, NewYork, New York, USA.
  • Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Medicine, Rush University Medical Center, Chicago, Illinois, USA.

ORCID-Profile: Davey M Smith, Sydney Ramirez, Camila H Coelho, Jennifer Manne-Goehler, Xingye Wu, Farhoud Faraji, Nathaniel Bloom, Amber Myers, Urvi M Parikh, Amy L Heaps, Rachel A Bender Ignacio, Jonathan Z Li, David Alain Wohl, Scott F Sieg, Kara W Chew

Förderung

  • NIAID NIH HHS
  • NCATS NIH HHS
  • NCI NIH HHS
  • NIH HHS
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Smith, D. M., Weir, I. R., Ramirez, S., Coelho, C. H., Manne-Goehler, J., Aziz, M., Benson, C. A., Wu, X., Hyer, R., Dhillon, P. K., Faraji, F., Bloom, N., Myers, A., Ramezani-Rad, P., Lopez, P. G., Parikh, U. M., Heaps, A. L., Javan, A. C., Bender Ignacio, R. A., …, & Chew, K. W. (2026). Impact of COVID-19 Monoclonal Antibody Therapy on Subsequent Vaccine-elicited SARS-CoV-2 Immune Responses. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiag091

Vancouver

Smith DM, Weir IR, Ramirez S, Coelho CH, Manne-Goehler J, Aziz M, et al. Impact of COVID-19 Monoclonal Antibody Therapy on Subsequent Vaccine-elicited SARS-CoV-2 Immune Responses. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiag091

BibTeX
@article{Smith2026,
  author = {Smith, Davey M and Weir, Isabelle R and Ramirez, Sydney and Coelho, Camila H and Manne-Goehler, Jennifer and Aziz, Mariam and Benson, Constance A and Wu, Xingye and Hyer, Randall and Dhillon, Preeti K and Faraji, Farhoud and Bloom, Nathaniel and Myers, Amber and Ramezani-Rad, Parham and Lopez, Paul G and Parikh, Urvi M and Heaps, Amy L and Javan, Arzhang Cyrus and Bender Ignacio, Rachel A and Li, Jonathan Z and Greninger, Alexander L and Daar, Eric S and Wohl, David Alain and Crotty, Shane and Sieg, Scott F and Chew, Kara W},
  title = {Impact of COVID-19 Monoclonal Antibody Therapy on Subsequent Vaccine-elicited SARS-CoV-2 Immune Responses},
  journal = {The Journal of Infectious Diseases},
  year = {2026},
  doi = {10.1093/infdis/jiag091}
}
Kostenlos starten →